All In Biotech

Drug Trial Radar · NCT05064852

A Real-world Study of the Safety and Efficacy of Surufatinib in the Treatment of Biliary Tract Carcinoma

Last checked: Nov 20, 2026Latest source record: Oct 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

200

Planned (sponsor's estimate)

Start

Sep 20, 2021

Primary completion

Dec 20, 2022

Study completion Dec 20, 2023

Sponsor

Lead sponsor
Qilu Hospital of Shandong UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 1, 2021

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a prospective, single-arm, open-label,multi-center, observational real-world clinical study to observe and evaluate the efficacy and safety of Surufatinib in the treatment of patients with biliary tract cancer (BTC).

Conditions

  • Biliary Tract Carcinoma

Interventions

  • SurufatinibDrug

    The study is a real-world study. According to the actual medical history of patients, the usage of Surufatinib was collected.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS)Time frame: 6 months after the last patient enrolled

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.